Toll-like receptors (TLRs) are crucial to trigger anticancer immune responses. Despite the promise of TLR agonists as potential anticancer agents, few have reached the clinics due to concerns related ...

Small-cell lung cancer accounts for about 10%-15% of all lung cancers, yet its molecular pathogenesis remains largely ...

It is in with the new and out with the old today as the first session of the 119 th U.S. Congress is called to order. Although Republicans will control both the House and Senate for the next two years ...

The U.K. is embarking on the biggest overhaul of clinical trials regulations in 20 years in a bid to retake ground that was lost following Brexit, when the Medicines and Healthcare products Agency was ...

Companies working in the field of women’s health have long struggled for funding, but as the number of these companies increase and new dedicated venture capital funds emerge, the conversation is ...

Biopharma companies secured $102.15 billion in funding in 2024, a 44% increase from $70.97 billion in the full-year 2023 and significantly higher than the $60.81 billion raised in 2022. December ...

Around the end of every year, the media reports on pregnancy and women who give birth on the last and first days of the new year. They tell their stories, the names of their babies and the cities ...

The dengue virus (DENV) is a single-stranded RNA virus with increasing worldwide prevalence causing severe mosquito-borne viral infections. Therefore, effective strategies to prevent and treat DENV ...

Institut Pasteur Korea has signed a memorandum of understanding (MOU) with four Pohang University of Science and Technology (POSTECH)-affiliated research institutes with the aim of pursuing joint ...

Psychedelic drugs continued to make regulatory and clinical headway, as non-believers converted to believers in the category once regarded with skepticism, to say the least.

After raising AU$16.75 million (US$10.4 million) in a series A round, Celosia Therapeutics Pty Ltd. is heading toward the clinic with its novel gene therapy that targets TDP-43, a protein directly ...

Balt Group SAS recently secured €355 million (US$365 million) in funding to refinance its debt, invest in research and accelerate its growth. The French-based provider of interventional neuroradiology ...